I Ask This Of You!
I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.
I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.
This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns.
Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.
This is a free site for all with no advertisements.
Thank you for visiting!
Friday, June 20, 2014
Wednesday, June 18, 2014
Largest-ever Trial in Parkinson's Disease Shows that for Long-term Treatment Levodopa is Better than Newer Drugs
Tuesday June 10, 2014
Wednesday June 11, 2014
spectrum of symptoms, including those of Parkinson's Disease. It is characterised by
abnormal deposits of calcium in areas of the brain that control movement, including the basal
ganglia and the cerebral cortex. For more information go to Fahr's Syndrome :
Symptoms of Fahr's Syndrome that are similar to those of
Parkinson's Disease may include deterioration of motor function,
dementia, dysarthria (poorly articulated speech), tremors, muscle
rigidity, a mask-like facial appearance, shuffling gait, and a
"pill-rolling" motion of the fingers. These symptoms generally
occur later in the development of the disease. More common
symptoms of Fahr's Syndrome include dystonia (disordered
muscle tone) and chorea (involuntary, rapid, jerky movements).
The age of onset of Fahr's Syndrome is typically in the 40s or
50s, which is similar to Parkinson's Disease, although it can also
occur at any time in childhood or adolescence.
Due to the possible similarity of symptoms to those of Parkinson's Disease, Fahr's Syndrome
should be considered as an important differential diagnosis in cases of Parkinsonism.
Monday, June 16, 2014
can kill nerve cells (green) by
tagging the s15 ribosomal protein (purple), a cog in a cell’s
Courtesy of Dawson lab, JHU
Morris K. Udall Center of
Excellence for Parkinson’s Disease.
attacks nerve cells in many parts of the nervous system, most notably in a brain region called the substantial
nigra, which releases dopamine, a chemical messenger important for movement. Initially, Parkinson’s disease
causes uncontrolled movements; including trembling of the hands, arms, or legs. As the disease gradually
patients lose ability to walk, talk or complete simple tasks.
leading genetic cause. They have been implicated in as many as 10 percent of inherited forms of the disease
and in aboutt 4 percent of patients who have no family history. One study showed that the most common LRRK2 mutation, called G2019S, may be the cause of 30-40 percent of all Parkinson’s cases in people of North
African Arabic descent.
groups. The process of phosphorylation helps regulate basic nerve cell function and health. Previous studies
suggest that disease-causing mutations, like the G2019S mutation, increase the rate at which LRRK2 tags
molecules. Identifying the molecules that LRRK2 tags provides clues as to how nerve cells may die during
experiments performed on human kidney cells suggested that LRRK2 tags ribosomal proteins. These proteins
combine with other molecules, called ribonucleic acids, to form ribosomes, which are the cell’s protein-making
had greater levels of phosphorylated s15 than seen in controls.
derived from rats or from human embryonic stem cells. Genetically engineering the cells to have a LRRK2 mutant
gene increased the amount of cell death and phosphorylated s15. In contrast, the researchers prevented cell death
when they engineered the cells to also make a mutant s15 protein that could not be tagged by LRRK2.
disease,” said Dr. Dawson.
the LRRK2 mutant protein induced nerve cell damage and movement disorders. Dr. Dawson’s team found that
the brains of these flies had increased levels of phosphorylated s15 and that engineering the flies so that s15
could not be tagged by LRRK2 prevented cell damage and restored normal movement.
anisomycin, a drug that blocks protein production, prevented nerve cell damage and restored the flies’ movement
t even though levels of s15 phosphorylation remained high.
future therapies as might other strategies which decrease bulk protein synthesis or increase the cells’ ability to
cope with increased protein metabolism. They also think that a means to measure s15 phosphorylation could also
act as a biomarker of LRRK2 activity in treatment trials of LRRK2 inhibitors.
Stem Cell Research Fund (2007-MSCRFI-0420-00, 2009-MSCRFII-0125-00, 2013-MSCRFII-0105-00), and
the New York Stem Cell Foundation.
disease,” Cell, April 10, 2014. DOI: 10.1016/j.cell.2014.01.064
Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the
primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about
NIH and its programs, visithttp://www.nih.gov.
Please watch video: